Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics
Tirthankar Sen, Rajkumar P. Thummer
Neurotoxicity Research (2022) Vol. 40, Iss. 5, pp. 1597-1623
Open Access | Times Cited: 22

Showing 22 citing articles:

Research progress of PROTACs for neurodegenerative diseases therapy
Zhifang Cai, Zunhua Yang, Huilan Li, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107386-107386
Closed Access | Times Cited: 8
Thalamic Alterations in Motor Neuron Diseases: A Systematic Review of MRI Findings
Sana Mohammadi, Sadegh Ghaderi, Mahdi Mohammadi, et al.
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 4, pp. 77-77
Open Access | Times Cited: 6
Therapeutic approaches targeting aging and cellular senescence in Huntington's disease
Asif Ahmad Bhat, Ehssan Moglad, Muhammad Afzal, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 10
Open Access | Times Cited: 6
The Multifaceted Role of WNT Signaling in Alzheimer’s Disease Onset and Age-Related Progression
William W. Kostes, David A. Brafman
Cells (2023) Vol. 12, Iss. 8, pp. 1204-1204
Open Access | Times Cited: 13
Induced pluripotent stem cell-derived and directly reprogrammed neurons to study neurodegenerative diseases: The impact of aging signatures
Simona Aversano, Carmen Caiazza, Massimiliano Caiazzo
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 19
Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients
Laura Siles, Sheila Ruiz‐Nogales, Arnau Navinés‐Ferrer, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 64-79
Open Access | Times Cited: 12
Advances in stem cell and other therapies for Huntington’s disease: An update
L. A. Conner, Bhairavi Srinageshwar, Bakke Jl, et al.
Brain Research Bulletin (2023) Vol. 199, pp. 110673-110673
Open Access | Times Cited: 12
CRISPR/Cas9 Technology and Its Advancements in Targeting Huntington's Disease: A Comprehensive Review
Sunıl Dutt Purohıt, Ayanangshu Nayak, Vibha Rani, et al.
Advances in Science, Technology & Innovation/Advances in science, technology & innovation (2025), pp. 157-174
Closed Access
Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems
Nguyễn Phương Thảo, Thuy-vi Nguyen, Soyeun Park
Journal of Pharmaceutical Investigation (2025)
Closed Access
Cell reprogramming therapy for Parkinson’s disease
Wenjing Dong, Shuyi Liu, Shangang Li, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 11, pp. 2444-2455
Open Access | Times Cited: 9
CRISPRi: a way to integrate iPSC-derived neuronal models
Sarah N. J. Franks, Rachel Héon-Roberts, Brent J. Ryan
Biochemical Society Transactions (2024) Vol. 52, Iss. 2, pp. 539-551
Open Access | Times Cited: 3
Mapping the future of oxidative RNA damage in neurodegeneration: Rethinking the status quo with new tools
H. O. Wheeler, Assael A. Madrigal, Isaac A. Chaim
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 46
Open Access | Times Cited: 3
Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia
Julie J. McInvale, Peter Canoll, Gunnar Hargus
Brain Pathology (2024) Vol. 34, Iss. 4
Open Access | Times Cited: 2
Human olfactory neurosphere-derived cells: A unified tool for neurological disease modelling and neurotherapeutic applications
Saad Irfan, Maudlyn O. Etekochay, Atanas G. Atanasov, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 10, pp. 6321-6329
Open Access | Times Cited: 2
Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson’s disease
Jiangbo Qu, Na Liu, Lu Gao, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 6
CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis
Yajun Shi, Yan Zhao, Likui Lu, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 2
Modeling Alzheimer's Disease using Cerebral Organoids: Current Challenges and Prospects
Ayodeji Zabdiel Abijo, S Olatunji, Stephen Taiye Adelodun, et al.
Brain Organoid and Systems Neuroscience Journal (2024)
Open Access
CRISPR/Cas9 gene editing: A new hope for Parkinson's disease
Sonali Hanjankar, Akash Haria, R. Agarwal, et al.
Elsevier eBooks (2024), pp. 527-565
Closed Access
Epigenetic manipulation and gene regulation using the CRISPR/Cas system for neurodegenerative diseases
Josephine Esposto
Elsevier eBooks (2024), pp. 119-133
Closed Access
Clinical trials for neurodegenerative diseases
Shasthara Paneyala, Paul Emmanuel L. Yambao, Jehath Syed, et al.
Elsevier eBooks (2024), pp. 499-526
Closed Access
Innovative Discoveries in Neurosurgical Treatment of Neurodegenerative Diseases: A Narrative Review
Matthew C. Findlay, Majid Khan, Mrinmoy Kundu, et al.
Current Alzheimer Research (2023) Vol. 20, Iss. 6, pp. 394-402
Closed Access | Times Cited: 1
Advances towards personalized therapies for Stargardt disease
Di Huang, Samuel McLenachan, Fred K. Chen
Expert Review of Ophthalmology (2023) Vol. 18, Iss. 5, pp. 315-325
Closed Access
Page 1

Scroll to top